An Italian research group has developed two innovative molecular techniques (RT-QuIC and PMCA) for an early and definitive detection of neurodegenerative diseases. They are looking for pharmaceutical companies active in the field of new treatments for neurodegenerative disorders or outsourcing companies involved in the process of drug discovery for neurological diseases. A regional grant can support the co-development of the research results by paying the costs of one year research fellowship.
The Italian research group with longstanding expertise in international reseach projects has developed innovative tecniques that can be tested by potential partners.
RT-QuIC and PMCA are fast in vitro assay that can detect disease-specific biomarkers with high sensitivity and specificity thus enabling early and definitive diagnosis of neurodegenerative diseases. These two techniques enable the detection of minute infectious prion proteins (undetectable by current diagnostic techniques) in peripheral tissues (e.g. urine, blood, cerebrospinal fluid and olfactory mucosa) of patients in early stages of neurodegenerative diseases and can model the process of protein misfolding and aggregation in vitro.
They are preparing a project proposal that can fund (thanks to a regional programme) one year fellowship grant.
They are looking for a company active in the field of new treatments for neurodegenerative disorders interested in the co-development of the technology. The company role will be to collaborate with the research group and the dedicated fellow in order to achieve the proof-of-concept (potentially ready to be used by the company).
Deadline of the call: 30/08/2017
Deadline for EoIs: 15/07/2017
- Specific area of activity of the partner: Type: pharmaceutical companies active in the field of new treatments for neurodegenerative disorders or outsourcing companies involved in the process of drug discovery for neurological diseases.
Role: co-development of the research results.
The two approaches are fast and can achieve an early and definitive diagnosis of dementia without the need of costly and invasive procedures. It is possible to obtain patients stratifications' useful for diagnostic and therapeutic purposes and assess the efficacy of different and innovative therapeutic compounds or drugs to interfere with the individual misfolding process. Moreover the techniques will allow the specific monitor of disease progression by analyzing the variation of disease-specific biomarkers, providing the patients with the most efficient compounds able to interfere with the molecular events and not only with the symptoms of the diseases.
01/05/2018 - Selling Online Internationally - Shetland
02/05/2018 - Selling Online Internationally - Orkney